Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
about
DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancerType-specific cell line models for type-specific ovarian cancer researchMismatch repair and treatment resistance in ovarian cancer.Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.Crosslinking of DNA repair and replication proteins to DNA in cells treated with 6-thioguanine and UVAVariations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel.Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cellsA rhodium(III) complex for high-affinity DNA base-pair mismatch recognitionThiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer.Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability.An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency.Drug metabolism and homologous recombination repair in radiosensitization with gemcitabineAlterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.Mechanisms of chemoresistance to alkylating agents in malignant glioma.New developments in the treatment of malignant gliomas.The role of DNA damage repair in aging of adult stem cellsPoly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activityDetection algorithm for the validation of human cell linesPharmaco(epi)genomics in ovarian cancer.Multiplex mapping of chromatin accessibility and DNA methylation within targeted single molecules identifies epigenetic heterogeneity in neural stem cells and glioblastoma.Predictive biomarkers for cancer therapy with PARP inhibitors.Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistanceIncreased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers.MLH1 deficiency enhances tumor cell sensitivity to ganciclovir.Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks.MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.Mechanisms of tolerance to DNA damaging therapeutic drugs.Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity.
P2860
Q28477059-6BDDDE78-D8DF-48FE-8D57-FD046896E16BQ28536689-49006827-A6B3-4AB3-AEFB-C9C8D196EFFEQ33252378-BB2CB0FA-3D07-4A59-BB5F-0C8E6BA4CF68Q33406808-347D5E68-DCE0-4C50-A283-BEF425E4E918Q33844623-93D02416-E308-4267-9B88-0380BBD16594Q33914285-96CA447A-F26B-4D0A-B06C-8A22A71BBE40Q34120722-A4C80B7D-8A48-4941-82FA-2DCDC7B74B11Q34180274-385E8CB6-0975-4FDD-92F9-5D0D9547BE11Q34728470-0B1D1543-DF37-4E15-8C42-E358E3C7FD6DQ34775052-7CFF0D2A-9A9B-4552-BD95-53BC14964D4FQ35036658-A30E368B-3F14-452B-A5B3-614035B8A0A1Q35124554-52CA8311-9496-41CE-9A81-C0984E86A6ECQ35268479-27C2467E-7808-43D3-AC08-93A3A64BB7C5Q36616482-B4A9A725-DBCD-47E3-8588-E72A014897A5Q36726010-D3D38308-407D-4260-87B8-010EF0811EB5Q36972696-3C500875-5493-4DFD-BFBE-7519D1D26101Q37045395-C3341395-81F1-4967-B0C6-C3CDDFFBFD1FQ37089235-7044AF05-0460-47B9-8E17-A6A7E459C4D0Q37169146-769AE64C-C47F-444B-A415-F9176ADC3DE0Q37346198-2F71C014-432F-4FDA-A993-DB53C7392CE1Q37550256-9A84A1EF-3DCE-42AF-81C2-4C0E4FD75569Q38137764-45E62F6F-B7D5-4731-975E-EE8DD9B143BAQ38797514-F38464AE-258E-4ED2-96C6-3C54BAF41EE1Q39599991-6956267D-4EE9-45E2-A855-32ADD3008E27Q39870596-C84EA932-6E7B-4D07-BD72-B0A9B1DAD5DDQ40244137-09F000EE-F024-4D09-9639-E17996E04690Q43211296-6BFB8F2D-B92F-444F-B390-350751F4B489Q43829355-73A7DFC0-66A8-481E-BC82-560AF35A7159Q44204619-D51DB73C-94BD-4BDC-A00F-7FDD0813077C
P2860
Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@ast
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@en
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@nl
type
label
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@ast
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@en
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@nl
prefLabel
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@ast
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@en
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@nl
P2093
P356
P1476
Characterization of MLH1 and M ...... he NCI anticancer drug screen.
@en
P2093
P2888
P304
P356
10.1007/S002800000186
P577
2000-01-01T00:00:00Z
P6179
1032144846